Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the low density lipoprotein cholesterol (LDL-C)
lowering effect of Bococizumab (PF-04950615;RN316) administered subcutaneously at every two
weeks (Q14D) in hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a
stable dose of atorvastatin, or who are naïve to a treatment by lipid lowering drug and whose
LDL-C is not controlled.